Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints

被引:2
作者
Martinez, Jordi Cortes [1 ]
Geskus, Ronald B. [2 ,3 ]
Kim, Kyung Mann [4 ]
Melis, Guadalupe Gomez [1 ]
机构
[1] Univ Politecn Cataluna, Dept Stat & Operat Res, Jordi Girona 31, Barcelona 08034, Spain
[2] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam
[3] Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England
[4] Univ Wisconsin, Dept Biostat & Med Informat, 600 Highland Ave, Madison, WI 53792 USA
基金
英国惠康基金;
关键词
Treatment Effect; Composite endpoint; Randomized Controlled Trial; Progression-Free Survival; Simulation; Copula; Non-Proportional Hazards; DOUBLE-BLIND; SURVIVAL;
D O I
10.1186/s12874-021-01286-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Sample size calculation is a key point in the design of a randomized controlled trial. With time-to-event outcomes, it's often based on the logrank test. We provide a sample size calculation method for a composite endpoint (CE) based on the geometric average hazard ratio (gAHR) in case the proportional hazards assumption can be assumed to hold for the components, but not for the CE. Methods The required number of events, sample size and power formulae are based on the non-centrality parameter of the logrank test under the alternative hypothesis which is a function of the gAHR. We use the web platform, CompARE, for the sample size computations. A simulation study evaluates the empirical power of the logrank test for the CE based on the sample size in terms of the gAHR. We consider different values of the component hazard ratios, the probabilities of observing the events in the control group and the degrees of association between the components. We illustrate the sample size computations using two published randomized controlled trials. Their primary CEs are, respectively, progression-free survival (time to progression of disease or death) and the composite of bacteriologically confirmed treatment failure or Staphylococcus aureus related death by 12 weeks. Results For a target power of 0.80, the simulation study provided mean (+/- SE) empirical powers equal to 0.799 (+/- 0.004) and 0.798 (+/- 0.004) in the exponential and non-exponential settings, respectively. The power was attained in more than 95% of the simulated scenarios and was always above 0.78, regardless of compliance with the proportional-hazard assumption. Conclusions The geometric average hazard ratio as an effect measure for a composite endpoint has a meaningful interpretation in the case of non-proportional hazards. Furthermore it is the natural effect measure when using the logrank test to compare the hazard rates of two groups and should be used instead of the standard hazard ratio.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: Update
    Bratton, Daniel J.
    Choodari-Oskooei, Babak
    Royston, Patrick
    STATA JOURNAL, 2015, 15 (02) : 350 - 368
  • [22] A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome
    Barthel, Friederike M-S.
    Royston, Patrick
    Parmar, Mahesh K. B.
    STATA JOURNAL, 2009, 9 (04) : 505 - 523
  • [23] Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?
    Phadnis, Milind A.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [24] Approximating the Baseline Hazard Function by Taylor Series for Interval-Censored Time-to-Event Data
    Chen, Ding-Geng
    Yu, Lili
    Peace, Karl E.
    Lio, Y. L.
    Wang, Yibin
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (03) : 695 - 708
  • [25] Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization
    LeClair, Jessica
    Massaro, Joseph
    Sverdlov, Oleksandr
    Gordon, Leslie
    Tripodis, Yorghos
    STATISTICS IN MEDICINE, 2022, 41 (30) : 5810 - 5829
  • [26] Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints
    Uozumi, Ryuji
    Hamada, Chikuma
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (01) : 84 - 100
  • [27] Assessing accuracy of Weibull shape parameter estimate from historical studies for subsequent sample size calculation in clinical trials with time-to-event outcome
    Phadnis, Milind A.
    Sharma, Palash
    Thewarapperuma, Nadeesha
    Chalise, Prabhakar
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 17
  • [28] Modeling time-to-event (survival) data using classification tree analysis
    Linden, Ariel
    Yarnold, Paul R.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2017, 23 (06) : 1299 - 1308
  • [29] Prediction of a time-to-event trait using genome wide SNP data
    Kim, Jinseog
    Sohn, Insuk
    Son, Dae-Soon
    Kim, Dong Hwan
    Ahn, Taejin
    Jung, Sin-Ho
    BMC BIOINFORMATICS, 2013, 14
  • [30] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
    Rulli, Eliana
    Ghilotti, Francesca
    Biagioli, Elena
    Porcu, Luca
    Marabese, Mirko
    D'Incalci, Maurizio
    Bellocco, Rino
    Torri, Valter
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1456 - 1463